Brentuximab vedotin (Usage)
Brentuximab vedotin is a targeted cancer therapy that is used to treat certain types of Hodgkin lymphoma and non-Hodgkin lymphoma. It is also used to treat advanced-stage classical Hodgkin lymphoma after autologous stem cell transplantation.
Hodgkin lymphoma:
- First-line treatment: Brentuximab vedotin can be used as a first-line treatment for advanced-stage classical Hodgkin lymphoma.
- Relapsed or refractory Hodgkin lymphoma: It can also be used to treat Hodgkin lymphoma that has come back after treatment or that has not responded to treatment.
- After autologous stem cell transplantation: Brentuximab vedotin can be used to reduce the risk of relapse in patients with advanced-stage classical Hodgkin lymphoma who have undergone autologous stem cell transplantation.
Non-Hodgkin lymphoma:
System anaplastic large cell lymphoma (ALCL): Brentuximab vedotin is approved for the treatment of systemic ALCL,
a type of non-Hodgkin lymphoma.